Aramayo Hits 44% for Oscar Nom After BAFTA Upset, But US Campaign Is MIA

Robert Aramayo's BAFTA Upset Over DiCaprio and Chalamet Just Rewrote the Oscar Conversation

Four months ago, Robert Aramayo walked into the BAFTAs as a near-anonymous entrant and walked out holding the Best Actor trophy. His portrayal of John Davidson, a Scottish man with severe Tourette's syndrome, in the indie biopic I Swear beat Leonardo DiCaprio (One Battle After Another), Timothée Chalamet (Marty Supreme), Ethan Hawke (Blue Moon), Michael B. Jordan (Sinners), and Jesse Plemons (Bugonia). According to British GQ, most prognosticators had framed the Best Actor race as a two-man duel between Chalamet and DiCaprio. Aramayo's name wasn't in the conversation.

Now it is. Prediction markets tracking the 2027 Best Actor Oscar nomination have priced Aramayo at 44% implied probability, more than doubling from a period low of 20% over just three days. That +24 percentage point surge is the kind of breakout move that typically signals a specific catalyst. In this case, the catalyst is clear: the BAFTA result proved Aramayo can beat the two biggest names in the race when voters actually weigh the performances side by side.

Loading live prices…

The February ceremony also handed Aramayo the EE Rising Star award, per The Independent, making him a double winner on a night that was supposed to crown an established star. His prior credits include Game of Thrones and The Rings of Power, but neither put him on the awards map. The BAFTA win did that in a single evening.

From 20% to 44%: What Aramayo's Oscar Nomination Odds Actually Tell Us

A jump from 20% to 44% means Aramayo has moved from a long-shot curiosity to near-coin-flip contender in the eyes of the market. At 44%, the aggregate implies roughly one-in-two odds that he secures one of the five Best Actor nomination slots when the Academy announces its shortlist on January 21, 2027.

The move deserves scrutiny. A +24 percentage point swing in three days, absent a new trailer, a festival premiere, or a campaign launch, suggests the BAFTA result's implications are still being digested by the market rather than a fresh piece of news triggering the spike. There have been no notable updates regarding Aramayo's Oscar prospects in the past two weeks, according to available reporting. The price action appears to reflect a delayed repricing of existing information rather than a reaction to something new.

Context matters here: the per-platform spread shows Kalshi at 17% and Polymarket at 72%, a gap wide enough to undermine confidence in the blended 44% figure. When two platforms disagree by 55 percentage points on the same outcome, the "consensus" number is more arithmetic artifact than market signal. Traders on Polymarket are pricing Aramayo as a near-lock for a nomination slot. Kalshi's market treats him as a fringe possibility. One of these platforms is dramatically wrong.

'I Swear' Hasn't Opened in the US Yet, and That's a Major Asterisk

Here is the concrete problem with pricing Aramayo at or near 50%: I Swear was scheduled for US release in April 2026, meaning American Oscar voters have only just been able to see the performance that beat DiCaprio and Chalamet at the BAFTAs four months ago. The market is pricing a nomination before the domestic reception is even established.

Oscar nominations are determined by the Academy's roughly 10,000 members, who skew heavily American and vote based on screener access, theatrical impressions, and campaign exposure. A BAFTA win generates headlines, but it does not substitute for the grinding, months-long awards campaign that typically carries a contender from September through January. Aramayo has no FYC billboards on Sunset Boulevard. His distributor has not yet mounted a screener push. The trade press has not begun its annual rankings and predictions for the 2027 race, because that conversation traditionally ignites in the fall festival season.

The BAFTA-to-Oscar pipeline is real but imperfect. British Academy voters and Academy voters overlap, yet the BAFTA electorate skews toward UK-based members who may weight a British indie performance differently than the broader Academy membership. Aramayo's win proves the performance resonates with a certain voting pool. Whether it resonates with American voters who are only now encountering the film remains unproven.

The Case Against Aramayo: Five Slots, Six Months, and a Stacked Field

The strongest argument against the current price is structural. The Best Actor field for 2027 will include performances from films that haven't screened yet. Fall festival darlings from Venice, Telluride, and Toronto routinely reshape the nomination picture. Aramayo's BAFTA rivals, DiCaprio and Chalamet, will both be in the Oscar conversation with the same performances that lost to him in London, and their campaigns will benefit from studio machinery that an indie biopic cannot match.

The Independent reported that Aramayo's victory was considered a genuine upset precisely because he was relatively unknown compared to his seasoned competitors. That dynamic cuts both ways. In a BAFTA ceremony, the underdog narrative can carry an actor across the finish line. In a six-month Oscar campaign, name recognition, press availability, and distributor spending power compound over time. Aramayo's team will need to sustain momentum through a period where bigger names command more oxygen.

There is also the question of performance fatigue. I Swear premiered in 2025 and won its BAFTA in February 2026. By the time Oscar voting opens in late 2026 or early 2027, the performance will be more than a year old. Academy voters historically favor fresh discoveries over familiar ones, and the films arriving at fall festivals will have the advantage of recency.

Where the Smart Money Should Focus Next

The resolution date of January 21, 2027, is seven months away. Between now and then, several observable milestones will either validate or deflate the current 44% price. The first is the domestic critical reception of I Swear, which should become clear over the summer as US reviews accumulate. The second is whether Aramayo's distributor commits to a formal awards campaign, including screenings, Q&As, and trade advertising, in the September-November window. The third is the fall festival season itself: if a breakout male lead performance emerges from Venice or Toronto, Aramayo's slot in the top five becomes harder to defend.

At 44% aggregate, the market is treating Aramayo as a near-even proposition. The BAFTA win justifies serious consideration. But the massive Kalshi-Polymarket divergence, the absence of a US campaign, and seven months of runway for new contenders to emerge all argue that the current price has outrun the available evidence. The performance is proven. The campaign is not.